NCT06351332 - ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in MTNBC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

March 1, 2027

Study Completion Date

September 1, 2029

Conditions

Breast CancerBreast Cancer FemaleTriple Negative Breast CancerHormone Receptor Negative Malignant Tumor Breast TripleHER2-negative Breast Cancer

Interventions

DRUG

Azenosertib

WEE1 inhibitor, 25 or 100 mg tablet, taken orally per protocol.

DRUG

Carboplatin

Platinum coordination compound, 5-, 15-, 45-, and 60-mL vials, via intravenous (into the vein) infusion per institutional standards.

DRUG

Pembrolizumab

Humanized immunoglobulin G4 monoclonal antibody, 4-mL vials, via intravenous (into the vein) infusion per protocol.

Trial Locations (1)

RECRUITING

Dana-Farber Cancer Institute, Boston